Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)
Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Matteo Della Porta(University of Milan), Giusy Di Conza(University of Geneva), Tracey Hammett(University of Geneva), Paramjit Kaur(University of Geneva), Jasson Villarreal Hernandez(Institut Català d'Oncologia), Chiara Paoli(University of Genoa), Michael Lahn(University of Geneva), Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi), Armando Santoro(IRCCS Humanitas Research Hospital), Mario Tiribelli(University of Udine)
Cited by 0
Related Papers
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
|Blood|2014|722
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540